Organon & Co. (NYSE:OGN) Hits New 12-Month Low - Here's What Happened

Key Points

• Shares of Organon hit a new 52-week low of $5.76 on Monday with about 620,674 shares traded, and MarketBeat shows an average analyst rating of Reduce with an average target price of $8.50 (majority sell ratings).
• Organon missed Q4 estimates, reporting $0.63 EPS versus $0.73 expected and revenue down 5.3% year-over-year to $1.51 billion, while trading at a P/E of 8.02, a market cap of roughly $1.49 billion, and offering a small annualized dividend yield of 1.4%.

Shares of Organon & Co. (NYSE:OGN - Get Free Report) hit a new 52-week low during trading on Monday . The stock traded as low as $5.76 and last traded at $5.7650, with a volume of 620674 shares trading hands. The stock had previously closed at $5.84.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on OGN. Barclays upped their price target on Organon & Co. from $7.50 to $8.00 and gave the company an "underweight" rating in a research report on Tuesday, February 24th. Zacks Research downgraded shares of Organon & Co. from a "hold" rating to a "strong sell" rating in a research note on Thursday, January 29th. Finally, Wall Street Zen lowered shares of Organon & Co. from a "buy" rating to a "hold" rating in a report on Saturday, January 31st. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and five have given a Sell rating to the stock. Based on data from MarketBeat, Organon & Co. presently has an average rating of "Reduce" and an average target price of $8.50.

Organon & Co. Price Performance

The stock has a fifty day moving average of $7.47 and a two-hundred day moving average of $8.01. The company has a current ratio of 1.82, a quick ratio of 1.23 and a debt-to-equity ratio of 11.47. The stock has a market capitalization of $1.49 billion, a price-to-earnings ratio of 8.02, a PEG ratio of 0.54 and a beta of 0.60.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings data on Thursday, February 12th. The company reported $0.63 EPS for the quarter, missing analysts' consensus estimates of $0.73 by ($0.10). Organon & Co. had a return on equity of 122.01% and a net margin of 3.01%.The business had revenue of $1.51 billion during the quarter, compared to analyst estimates of $1.52 billion. During the same period in the prior year, the firm posted $0.90 EPS. Organon & Co.'s revenue for the quarter was down 5.3% compared to the same quarter last year. As a group, equities research analysts forecast that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 12th. Shareholders of record on Monday, February 23rd were issued a dividend of $0.02 per share. The ex-dividend date of this dividend was Monday, February 23rd. This represents a $0.08 dividend on an annualized basis and a yield of 1.4%. Organon & Co.'s dividend payout ratio is currently 11.27%.

Hedge Funds Weigh In On Organon & Co.

Institutional investors have recently modified their holdings of the stock. Foster Dykema Cabot & Partners LLC bought a new stake in shares of Organon & Co. during the third quarter valued at approximately $29,000. Farther Finance Advisors LLC raised its position in Organon & Co. by 87.8% in the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company's stock worth $31,000 after purchasing an additional 2,033 shares during the last quarter. Rothschild Investment LLC lifted its holdings in Organon & Co. by 73.1% during the 3rd quarter. Rothschild Investment LLC now owns 3,899 shares of the company's stock worth $42,000 after buying an additional 1,646 shares in the last quarter. Eurizon Capital SGR S.p.A. acquired a new position in Organon & Co. during the 4th quarter worth $44,000. Finally, Kestra Advisory Services LLC bought a new position in Organon & Co. in the 4th quarter valued at $47,000. 77.43% of the stock is owned by institutional investors.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.